News
Pan Amyloid
Immunotherapy
Towards a universal treatment for
amyloid-mediated diseases
Progress and limitations of new treatments
We are entering an exciting era for treating neurodegenerative diseases, with new antibody-based products targeting amyloid beta for Alzheimer’s patients. Despite high expectations, these treatments may have limited impact, as they target only one misfolded protein.
Effective against all misfolded proteins in amyloid-mediated diseases, both neurodegenerative and systemic.
It clears amyloid aggregates at the late stage of the disease for therapeutic application.
It inhibits early-stage aggregate formation, and dissolves early aggregates, supporting a preventative application.
Towards a universal treatment for
amyloid-mediated diseases
© Amyl Therapeutics